M. Reckner

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

P. Vyas, B. Graves, M. Andreeff, 2015, Clinical Cancer Research.

Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.

J. Blay, Y. Bang, H. Hirte, 2014 .

Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.

L. Vassilev, M. Andreeff, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.

L. Vassilev, M. Andreeff, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.